FDA Offers Full Approval for Amgen’s Blood Cancer Drug ‘Krypolis’

by Reshma Anand on  January 23, 2016 at 2:34 PM Corporate News
RSS Email Print This Page Comment
Font : A-A+

The US food and Drug Administration has announced that it has approved Amgen's supplemental new drug application for Kyprolis in combination with dexamethasone and Revlimid (lenalidomide) for the treatment of refractory multiple myeloma.
FDA Offers Full Approval for Amgen’s Blood Cancer Drug ‘Krypolis’
FDA Offers Full Approval for Amgen’s Blood Cancer Drug ‘Krypolis’

Krypolis can now be used for treating patients with relapse or refractory multiple myeloma who have received one to three treatment before.

The drug was approved as a single agent by the FDA in 2012 and now it has expanded it into full approval.

Amgen said, "The agency approved Kyprolis in combination with dexamethasone or with the drug lenalidomide plus dexamethasone for relapsed or refractory patients. It approved the drug as a single agent for patients with relapsed or refractory disease who have received one or more treatments."

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Drug Toxicity Thalassemia Cancer and Homeopathy Signature Drug Toxicity Cancer Facts Cancer Tattoos A Body Art Hairy Cell Leukemia Blood in Stools - Symptom Evaluation Bombay Blood Group 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive